University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.

Patients taking vancomycin were significantly more likely to carry vancomycin-resistant Enterococcus (VRE) 8 weeks after ...

Fecal microbiota transplantation was not inferior to vancomycin for the treatment of primary Clostridioides difficile ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, ...

Vancomycin, a glycopeptide antibiotic, is commonly used to treat gram-positive pathogens associated with vascular-access-related infections, such as coagulase negative Staphylococcus species, ...

Vancomycin remains one of the most widely used antibiotics for the treatment of Staphylococcus (including methicillin-resistant Staphylococcus aureus), Streptococcus, and Enterococcus infections.

Vancomycin is a generic prescription drug that’s used to treat certain types of bacterial infections in adults and children. Vancomycin’s cost may depend on factors such as your dosage ...

Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability. PLOS Pathogens , 2024; 20 (8): e1012422 DOI ...